These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6872895)

  • 21. Outbreaks of group B meningococcal disease--Florida, 1995 and 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Oct; 47(39):833-7. PubMed ID: 9780239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for control of meningococcal disease. Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control, Ottawa, Ontario, Canada.
    Can Commun Dis Rep; 1994 Feb; 20(3):17-27. PubMed ID: 8167604
    [No Abstract]   [Full Text] [Related]  

  • 23. [Meningococcal infections. Chemical prevention or preventive vaccination].
    Delville J
    Arch Belg Med Soc; 1973; 31(6):414-23. PubMed ID: 4592088
    [No Abstract]   [Full Text] [Related]  

  • 24. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
    Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
    Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of seroconversion and duration of immunity induced by the meningococcal serogroup C vaccine. Study included in the evaluation of the mass immunization of the population in the age group between 18 months and 19 years in the community of Madrid].
    Ramírez Fernández R
    Rev Esp Salud Publica; 1998; 72(5):401-6. PubMed ID: 9951331
    [No Abstract]   [Full Text] [Related]  

  • 26. [Meningococcal disease. new prevention strategies].
    Soult Rubio JA; Muñoz Sáez M; López Castilla JD
    An Esp Pediatr; 2001 Jan; 54(1):65-8. PubMed ID: 11181197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain).
    Martínez AI; Dominguez A; Oviedo M; Minguell S; Jansa JM; Codina G; Vazquez JA;
    Vaccine; 2009 May; 27(25-26):3496-8. PubMed ID: 19200816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vaccine coverage survey per cluster sampling after an antimeningococcal mass vaccination campaign at Niamey, Niger in 2000].
    de Chabalier F; Garba A; Chippaux JP
    Sante; 2001; 11(3):173-6. PubMed ID: 11641081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clustering of childhood meningococcal disease: a challenge for physicians, press and community.
    Dreyer MS; Eppes SC; Klein JD
    Del Med J; 1993 Nov; 65(11):711-4. PubMed ID: 8299824
    [No Abstract]   [Full Text] [Related]  

  • 31. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of meningococcal disease: guidance for consultants in communicable disease control. PHLS Meningococcal Infections Working Group and Public Health Medicine Environmental Group.
    Commun Dis Rep CDR Rev; 1995 Dec; 5(13):R189-95. PubMed ID: 8556102
    [No Abstract]   [Full Text] [Related]  

  • 33. An epidemic of meningococcal infection at Zaria, Northern Nigeria. 3. Meningococcal carriage.
    Hassan-King M; Greenwood BM; Whittle HC; Abbott JD; Sutcliffe EM
    Trans R Soc Trop Med Hyg; 1979; 73(5):567-73. PubMed ID: 531911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Susceptibility to antimicrobial drugs used in the prophylaxis of meningococcal disease: situation after an epidemic wave].
    Arreaza L; de la Fuente L; Fernández S; Vázquez JA
    Rev Esp Quimioter; 2000 Jun; 13(2):182-6. PubMed ID: 10918092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Epidemiology and prevention of meningococcal infection abroad].
    Chaĭka NA
    Tr Inst Im Pastera; 1983; 61():164-79. PubMed ID: 6379993
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effectiveness of seroconversion of the Neisseria meningitidis serogroup C vaccine, duration of antibody levels in the Autonomic Community of Extremadura].
    Ramos Aceitero JM
    Rev Esp Salud Publica; 1998; 72(5):411-4. PubMed ID: 9951333
    [No Abstract]   [Full Text] [Related]  

  • 37. [Epidemiology and clinic of meningococcal infections. Indications for immunization].
    Goetz O; Peller P
    MMW Munch Med Wochenschr; 1980 Oct; 122(41):1411-2. PubMed ID: 6780820
    [No Abstract]   [Full Text] [Related]  

  • 38. Meningococcal disease and prevention at the Hajj.
    Borrow R
    Travel Med Infect Dis; 2009 Jul; 7(4):219-25. PubMed ID: 19717104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002.
    Brooks R; Woods CW; Benjamin DK; Rosenstein NE
    Clin Infect Dis; 2006 Jul; 43(1):49-54. PubMed ID: 16758417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.